Stock Financial Ratios and Split History

CRSP / CRISPR Therapeutics AG financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)2,431.95
Enterprise Value ($M)2,180.45
Book Value ($M)187.83
Book Value / Share4.00
Price / Book12.95
NCAV ($M)164.87
NCAV / Share3.51
Price / NCAV14.98
Income Statement (mra) ($M)
Net Income-68.36
Balance Sheet (mrq) ($M)
Cash & Equivalents0.00
Cash / Share0.00
Quick Ratio17.12
Current Ratio17.12
Share Statistics
Preferred Stock Shares Outstanding0
Common Stock Shares Outstanding40,592,248
Common Shares Outstanding46,976,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.36
Return on Assets (ROA)-0.18
Return on Equity (ROE)-0.29
Identifiers and Descriptors
Central Index Key (CIK)1674416
Industry Groups

Split History

Stock splits are used by CRISPR Therapeutics AG to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Peers -

Related News Stories

Analyzing CRISPR Therapeutics' Q4 And Full-Year 2017 Results

2018-03-20 seekingalpha
Editor's note: Seeking Alpha is proud to welcome SA Joseph Sancio as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » (10-0)

Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment. (727-2)

Does Crispr Therapeutics AG Deserve This Massive Rally?

2018-03-19 investorplace
Crispr Therapeutics AG (NASDAQ:CRSP) is one of the hottest biotech names in the market today. After going sideways for much of last year, Crispr stock surged to a massive 106% performance year-to-date. Obviously, CRSP has momentum on its side, but can this ridiculous rally continue forward? (24-0)

Portfolio Strategy: How To Build An Impregnable Defense For A Momentous Offense?

2018-03-16 seekingalpha
We share with readers approaches to creating an impregnable defense against a bear market as well as the high volatility of the bioscience sector. (83-1)

Regenxbio: Substantial Unlocked Value In The MPS Franchises

2018-03-13 seekingalpha
There is substantial unlocked value in its NAV. The technology platform is currently being investigated in 20 different conditions. (30-0)

CUSIP: H17182108